Project Grant R21CA288677
Award Date
7/9/24
Completion Date
6/30/26
Dollars Obligated
$235K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06510, USA
Similar Awards
This Project Grant award of $158,365 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will support research to understand the impact of NRF2 activation on lung squamous cell carcinoma (LUSC) initiation and progression. The award recipient, the University of North Carolina at Chapel Hill, will develop a novel genetically-engineered mouse model to assess how activated NRF2 affects LUSC incidence, tumor characteristics, gene expression, and the tumor...
The National Cancer Institute (NCI) awarded a $160,330 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the University of Illinois to develop novel human-relevant lung adenocarcinoma models. The two-year project aims to introduce oncogenic mutations into primary human lung stem and progenitor cells and generate organoid and xenograft models. The goal is to create models that better capture the initiation, progression, and composition of primary human lung adenocarcinoma...
This $602,315 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test prevention agents. The primary objectives are to: 1) Define the human relevance of the in vivo NTCU/smoke mouse model of lung SCC premalignancy, 2) Validate an ex vivo precision cut lung slice approach to screening new...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410 to New York University School of Medicine to conduct research aimed at understanding the molecular mechanisms underlying the adeno-to-squamous transition observed in non-small cell lung cancer patients treated with KRAS inhibitors. The key objectives are to: Identify chromatin regulators that drive the adeno-to-squamous transition through a perturbation screen, and then...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The $256,487 grant, effective August 13, 2024, supports a 5-year research project to develop multimodal predictive models for non-small cell lung cancer (NSCLC) using real-world data sources such as circulating tumor DNA sequencing, tumor genomics, and clinician notes. The goal is to improve risk stratification and clinical...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research program) provides $701,538 to the Icahn School of Medicine at Mount Sinai to investigate the epigenomic drivers and lineage evolution of a novel small cell lung cancer (SCLC) subtype characterized by the NKX2-1 transcription factor. The research aims to: 1) determine how cell-of-origin and NKX2-1 impact the evolution and maintenance of this SCLC epigenomic state, 2) elucidate...
This $566,523 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support research to identify interception targets in persistent lung premalignant lesions (PMls) that are at high risk of progressing to lung cancer. The awardee, the University of Colorado-Denver, will use a reverse translational approach to: 1) identify interception targets in the persistence profile in clinical trial biopsies, 2)...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, is focused on uncovering the core mechanisms driving lineage plasticity in EGFR-mutant lung adenocarcinoma (LUAD). The $631,156 award will fund a 5-year research project conducted by the Icahn School of Medicine at Mount Sinai to systematically investigate the genetic, transcriptomic, and epigenomic changes underlying the transformation of LUAD to the more...
This Project Grant award of $730,398.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research aims to comprehensively characterize the lung cancer genomic landscape in patients of African ancestry. The key products and services to be delivered under this 5-year award include: Identifying and validating genomic differences between lung cancer patients of African and European ancestry, with a focus on drug targetable and...
This federal Project Grant award from the National Institutes of Health's National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,400.00 in funding to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding the metabolic mechanisms that drive the emergence and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The researchers will use mouse models and patient-derived xenograft models to manipulate components of the...